- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03569761
A Culturally-adapted Colorectal Cancer Screening Decision Aid Designed for American Indians
A Randomized Trial of a Culturally-adapted Colorectal Cancer Screening Decision Aid Designed for American Indians
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Colorectal Cancer (CRC) Screening Options. CRC is a unique cancer due to the multiple screening options including stool-based (fecal occult blood testing (FOBT) and fecal immunochemical testing (FIT)), and direct visualization (colonoscopy) options. Healthcare providers tend to recommend colonoscopy, although evidence indicates that many patients, especially low-income and racial and ethnic minorities, prefer stool-based testing for a variety of reasons. In our formative work with North Carolina tribes, the investigators found evidence of low awareness of stool-based tests among American Indians (AI) and healthcare provider preferences to recommend colonoscopy. The US Preventive Services Task Force (USPSTF) guidelines indicate that evidence does not support favoring one CRC screening test above the others, and that recommendations should be based on patient preferences among the screening options. However, patient's general lack of knowledge of CRC screening modalities, literacy barriers to understanding differences between options, and other communication barriers in the healthcare setting (e.g., limited physician time) make this recommendation difficult to implement in practice without appropriate tools and support. Multimedia decision aids provide a practical solution to overcome communication challenges by providing patients information using easy-to-understand graphics and narratives designed to help them understand options, think through what is important to them, and engage with healthcare providers and family in the decision-making process.
CRC Screening Decision Aids. A recent systematic review and meta-analysis found evidence that average risk patients (aged 50 and over) exposed to CRC screening decisions aids showed greater increases in knowledge, were more likely to be interested in getting screened, and more likely to be screened. Most research on decision aids has been conduct with majority White populations; a few studies have focused on patients with low socioeconomic status. To our knowledge, no CRC screening decision aid studies have focused on AI populations.Our team has expertise in adapting CRC screening decision aids for underserved populations. The investigators have used a rigorous, community- and patient-engaged process to adapt a decision aid previously shown to be effective among majority White populations. The process retains effective elements of the existing version and refines content using messages and messengers that are culturally-sensitive (beyond peripheral packaging of graphics and visual content). A version the investigators adapted for low-income Hispanics significantly improved Hispanic patient's CRC screening knowledge, patient-provider communication, self-efficacy, and intent, and when combined with navigation, significantly improved completion of screening.
AI Barriers to CRC Screening. AI may benefit from decision aids; yet, CRC screening decision aids have not been developed or tested with AI populations. Several studies have found that AI have lower awareness and knowledge about CRC screening options and low perceived susceptibility of CRC than White populations. Many qualitative studies also indicate social and cultural barriers to CRC screening. For example, AIs indicate taboos related to speaking of illness or of certain body parts and fatalistic cultural beliefs influence their attitudes and intentions to obtain preventive medical services. In addition, a history of unethical healthcare practices and mistreatment of AI by the US government has led to issues of mistrust. Recent studies have found that AI report negative perceptions of medical providers and mistrust in healthcare institutions as barriers to obtaining CRC screening. Decision aids can address low awareness of options and improve attitudes and intentions for screening, especially if the content and the messengers of the information are adapted for sensitivity to relevant socio-cultural barriers (e.g., spiritual advisors who are credible to AI endorse screening). For this proposal, the investigators propose to test a novel culturally-adapted decision aid that aims to improve knowledge, attitudes and intentions to obtain CRC screening and uses messaging developed with our tribal community partners to overcome health literacy and socio-cultural barriers.
Conceptual Framework. Our decision aid is informed by the Theory of Planned Behavior and Cultural Identity Theory. The Theory of Planned Behavior posits that individual's attitudes (i.e., how one feels about a behavior and the potential outcomes of the behavior), norms (i.e., the amount of social pressure one feels to perform a behavior), and agency (i.e., the extent that one feels in control and able to perform a behavior) impacts their intentions to and subsequent performance of a behavior. The investigators also draw upon Cultural Identity Theory and posit that one's cultural identity and corresponding values underlie how one receives and interprets communicated messages and how one communicates with others about these messages. Our culturally-adapted decision aid uses messages that address AI-specific attitudes, norms, agency and communication concerns.
Preliminary Studies. With developmental funding from UNC's Lineberger Comprehensive Cancer Center, the investigators followed a rigorous process to adapt a general population version of a CRC screening decision aid for AI. From January to May of 2016, the investigators conducted six focus groups (n=74) with AI (ages 50-75) and interviews with healthcare providers (n=8) from three North Carolina tribal communities. The investigators explored perspectives about cultural, communication, and literacy barriers to CRC screening, and identified critical themes regarding AI cultural identity and socio-cultural values that influence CRC screening. The investigators and our tribal partners have operationalized the themes into adaptations of the existing general population decision aid. The decision aid provides information on stool-based and colonoscopy tests, the two types readily available in the community. The investigators are filming and making edits to the decision aid, which will be completed and ready for pilot testing by December 2016. Themes from AI focus groups and operationalized changes to a culturally-adapted CRC screening decision aid Operationalized Changes Healthcare mistrust - concern that inappropriate medical tests are recommended by providers Religious advisor to provide information and conveys trust in CRC screening options AI collectivism - stronger 'family' and community orientation toward health than individual focus New messages emphasize the benefit of CRC screening to one's family and community Privacy concerns- indication of difficulties and discomfort talking about CRC screening with family Vignette that models family communication around CRC screening Fear of cancer and screening - fear of cancer and screening process reduces motivation for screening AI CRC survivor to share experience of being screened and treated early
Methods A. Setting Our current research is centered in North Carolina tribal communities, primarily with the Lumbee Tribe of North Carolina, a state-recognized tribe that is located in Southeastern North Carolina. There are 62,306 Lumbee tribal members, the majority of whom (48,494) live in Robeson county. As with AI populations across the US, North Carolina AI have high rates of poverty and low educational attainment. One-third (33%) of AI in Robeson County are below the federal poverty level compared to 17% in North Carolina overall.45As a state-recognized tribe, Lumbee are not eligible for services through the federally-funded Indian Health Service,44 and many Lumbee tribal members use safety-net and federally qualified health centers such as the Robeson Health Care Corporation (RHCC), partner on this grant (see letter of support) to obtain health services.Robeson Health Care Corporation is a federally qualified health center with six clinics located in Robeson and neighboring counties. RHCC serves over 14,000 patients per year; 40% are AI. Nearly all, 95.6% of RHCC patients are at or below 200% of the federal poverty line. According to recent reports, 6,295 RHHC patients were not up-to-date with CRC screening following recommended guidelines.RHHC also has a long history of research collaboration on cancer screening projects.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Lumberton, North Carolina, United States, 28358
- Robeson Health Care Corporation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 50-75
- Self-identify as AI (from any tribe)
- Are not up-to-date with recommended screening in accordance with USPSTF guidelines.
Exclusion Criteria:
- Patients who have a personal or family history of CRC or adenomatous polyps or inherited genetic conditions that increase CRC risk (familial adenomatous polyposis, Lynch syndrome, Turcot syndrome, Peutz-Jeghers syndrome, or MUTYH-associated polyposis)
- Unable to speak English
- Severe cognitive, visual, or hearing impairment that would prevent decision aid viewing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Decision Aid Video Intervention
Participants randomized to the intervention group will view the AI culturally-adapted CRC screening decision aid in a private room at a RHCC clinic.
The video will be viewed on an electronic tablet or laptop computer.
|
Information previously discussed in arm/group descriptions.
There will be baseline, post-encounter, and 5-month follow-up assessments.
|
ACTIVE_COMPARATOR: Control
Participants randomized to the control group will view an attention-control video about food safety in a private room at a RHCC clinic.
The video will be viewed on an electronic tablet or laptop computer.
The investigators chose the attention-control video so that the structure of the control arm mirrors the intervention arm.
The food safety topic was chosen to provide information that is reasonably salient to the control arm participants but that would not be likely to affect encounters with healthcare providers.
|
Information previously discussed in arm/group descriptions.
There will be baseline, post-encounter, and 5-month follow-up assessments.
Information previously discussed in arm/group descriptions.
There will be baseline, post-encounter, and 5-month follow-up assessments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CRC screening intentions
Time Frame: Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Measure of screening intent from prior CRC screening decision aid studies and assessed using a single categorical item regarding intentions to get CRC screening with four response options.
|
Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knowledge
Time Frame: Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Assessed by a six-item index (based on decision aid content).
Items include 1) the availability of more than one option for CRC screening; 2) the availability of a home screening test; 3) the recommended age to begin CRC screening; 4) FOBT screening test frequency; 5) the need for sedation (and companion driver) for colonoscopy procedure, and 6) the existence of a small but non-zero complication risk associated with having colonoscopy.
|
Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Attitudes
Time Frame: Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Assesses attitudes about how important items are for a participant's decision of whether or not to get CRC screening, including potential pros (e.g., having peace of mind after receiving clear findings) and cons (e.g., being worried or concerned that if you do the test you might find something wrong) with 4-point Likert-scale response options.
|
Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Perceived social norms
Time Frame: Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Assesses the participant's belief that family, friends, and doctors think he/she should be screened.
|
Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Personal agency
Time Frame: Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Assesses confidence to complete screening with 4-point Likert-scale response options (i.e., not at all confident, not very confident, confident, very confident).
|
Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
CRC screening preferences
Time Frame: Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Measures screening preferences from prior studies.
|
Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Healthcare provider communication
Time Frame: Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Assessed with a participant-reported measure of having had a CRC screening discussion with a healthcare provider in the prior 5 months based on items used in a national survey.
|
Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Family and friend communication
Time Frame: Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Assessed using a measured adapted from a study on family communication about cancer screening.
Participants asked to enumerate social network members and will be asked to identify members with whom they discussed CRC screening.
|
Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
CRC screening completion
Time Frame: Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Dichotomous indicator of whether or not the participant completed any of the recommended CRC screening tests.
|
Immediately after participant views their respective assigned video. Five (5) months following the encounter, a research assistant will call and administer a follow-up survey.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Leah Frerichs, PhD, University of North Carolina, Chapel Hill
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCCC 1711
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Colorectal Cancer Screening Decision Aid
-
Case Comprehensive Cancer CenterCompletedProstate CancerUnited States
-
University of PennsylvaniaCompletedBreast CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterUNC Cecil G. Sheps Center for Health Services ResearchCompletedNeoplasm of Lung | Decision Support Techniques | Mass ScreeningUnited States
-
Tufts UniversityCompletedProstate NeoplasmUnited States
-
University of SydneyNational Health and Medical Research Council, AustraliaUnknownColorectal NeoplasmsAustralia
-
Centers for Disease Control and PreventionUnknownProstate CancerUnited States
-
Pontificia Universidad Catolica de ChileComisión Nacional de Investigación Científica y TecnológicaRecruitingBreast Cancer | Breast Tumor | Mammary Cancer | Mammary TumorChile
-
Institut de Recerca Biomèdica de LleidaInstitut Català d'Oncologia; Hospital del Mar; Canary Islands Health ServiceCompletedBreast Cancer ScreeningSpain
-
Virginia Commonwealth UniversityBlue Cross Blue Shield; Allina Health SystemCompletedColorectal Cancer Screening | Shared Decision MakingUnited States
-
UNC Lineberger Comprehensive Cancer CenterCompletedLung Neoplasms | Primary Health Care | Decision Support Techniques | Early Detection of CancerUnited States